News & Events

May 4, 2021

CARISMA Therapeutics to Participate in Panel and Showcase Exhibit During Cellicon Valley ’21 Virtual Symposium

CARISMA’s Chief Medical Officer, Debora Barton, MD, will be participating in a panel discussion on May 6 at 2:15 pm ET entitled “Cell & Gene Startups & Innovation in Cellicon Valley” alongside other industry leaders during Cellicon Valley ’21 Virtual Symposium.” We will also showcase a virtual exhibit about CARISMA and our recent accomplishments for […]

Read More
April 28, 2021

CARISMA Therapeutics to Present Data at The American Society of Gene & Cell Therapy 24th Annual Meeting

PHILADELPHIA, April 28, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced findings from two studies accepted for virtual presentation at The American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting on Tuesday, May 11 – Friday, May 14. The findings mark the first […]

Read More
April 26, 2021

CARISMA Therapeutics Establishes Collaboration with Leading Cell Therapy Expert to Explore and Develop Allogeneic CAR-Macrophages

PHILADELPHIA, April 26, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has established a multi-year scientific collaboration with Bruce Blazar, MD, Regents Professor of Pediatrics, Division of Blood and Marrow Transplantation and Cellular Therapy at the University of Minnesota to investigate and develop […]

Read More
April 9, 2021

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting

PHILADELPHIA, April 9, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15. The accepted data reinforces the potential of CARISMA’s proprietary chimeric […]

Read More
March 18, 2021

CARISMA Therapeutics Announces First Patient Dosed in Landmark Clinical Study Evaluating Engineered Macrophages in Humans

PHILADELPHIA, March 18, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pennsylvania (Penn) and focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted […]

Read More
March 11, 2021

CARISMA THERAPEUTICS TO PRESENT AT SOLEBURY CAPITAL SPRING PRIVATE COMPANY SHOWCASE

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that Steven Kelly, the President & CEO, will present at a virtual investor conference in March. Solebury Trout Winter Private Company Showcase March 11, 2021 Presentations can be found here. About CARISMA Therapeutics Inc. CARISMA Therapeutics Inc. is a biopharmaceutical company […]

Read More
March 1, 2021

CARISMA Therapeutics Completes Series B Financing Totaling $59 Million

PHILADELPHIA, March 1, 2021 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA’s total capital raised to date to nearly $121 million. Click here for more information.

Read More
January 27, 2021

CARISMA THERAPEUTICS TO PRESENT AT UPCOMING VIRTUAL INVESTOR CONFERENCE IN JANUARY

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that Steven Kelly, the President & CEO, will present at a virtual investor conference in January. Solebury Trout Winter Private Company Showcase January 29, 2021 Presentations will be available Friday at the following link https://troutaccess.com/investor.php/participatingcompanies/details/company_hash/b45fdd7041c1afe62f350f48a3d42db3/conference_hash/e1e5eb88c06de1cbd628c42a940c8290 About CARISMA Therapeutics Inc. CARISMA Therapeutics […]

Read More
January 7, 2021

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million. Click here for more information.

Read More